Goal 2: Reduce Human Disease

Will Novel Therapies Create Bleeding Remission HHT and Angiogenic Disorders

Chronic bleeding due to epistaxis and gastrointestinal bleeding telangiectasia in HHT leads to transfusion dependence, iron infusion dependence,

decreased quality of life and premature death.


Novel therapies such as pomolidamide, Avastin and pazopanib may be new promising therapies to lead to remission in bleeding and reduce the burden of disease

Tags (Keywords associated with the idea)


1 net vote
2 up votes
1 down votes
Idea No. 1091